Advertisement
Screener

TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Stock Issued During Period, Value, Employee Stock Purchase Plan

1.5 / 5 stars · 18/60 Roast Me

TONIX PHARMACEUTICALS HOLDING CORP. Stock Issued During Period, Value, Employee Stock Purchase Plan

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • TONIX PHARMACEUTICALS HOLDING CORP. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $79.00K.
  • TONIX PHARMACEUTICALS HOLDING CORP. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $4.00K.
  • TONIX PHARMACEUTICALS HOLDING CORP. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-03-31 was $23.00K, a 20.69% decline year-over-year.
  • TONIX PHARMACEUTICALS HOLDING CORP. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-03-31 was $29.00K, a 27.50% decline year-over-year.
  • TONIX PHARMACEUTICALS HOLDING CORP. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $27.00K, a 6.90% decline from fiscal 2023.
  • TONIX PHARMACEUTICALS HOLDING CORP. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $29.00K, a 27.50% decline from fiscal 2022.
  • TONIX PHARMACEUTICALS HOLDING CORP. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $40.00K, a 58.33% decline from fiscal 2021.
  • TONIX PHARMACEUTICALS HOLDING CORP. stock issued during period, value, employee stock purchase plan for fiscal 2021 was $96.00K, a 4700.00% increase from fiscal 2020.
Period endStock Issued During Period, Value, Employee Stock Purchase Plan 3 monthStock Issued During Period, Value, Employee Stock Purchase Plan 12 month
2026-03-31$79.00K
10-Q · filed 2026-08-10
2024-12-31$27.00K
10-K · filed 2026-03-12
2024-09-30$4.00K
10-Q · filed 2025-11-10
2024-03-31$23.00K
10-Q · filed 2025-11-10
2023-12-31$29.00K
10-K · filed 2025-03-18
2023-03-31$29.00K
10-Q · filed 2024-11-12
2022-12-31$40.00K
10-K · filed 2024-04-01
2022-03-31$40.00K
10-Q · filed 2023-11-09
2021-12-31$96.00K
10-K · filed 2023-03-13
2021-09-30$68.00K
10-Q · filed 2022-11-07
2021-03-31$28.00K
10-Q · filed 2022-11-07
2020-12-31$2.00K
10-K · filed 2022-03-14
2020-03-31$2.00K
10-Q · filed 2021-11-08
2019-12-31$31.00K
10-K · filed 2021-03-15
2019-09-30$28.00K
10-Q · filed 2020-11-09
2019-03-31$3.00K
10-Q · filed 2020-11-09
2017-12-31$74.00K
10-K · filed 2019-03-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
ADC Therapeutics SA (ADCT)$0.163B-1.39
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
Annexon, Inc. (ANNX)United States$0.147B-4.22
PepGen Inc. (PEPG)United States$0.186B-1.73
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91